Skip to main content
MHTX logo

Manhattan Scientifics, Inc. (MHTX) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 $0.00 (0.00%)
Vol: 4.56M|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Manhattan Scientifics, Inc. (MHTX) trades at $0.0001. Sector: Healthcare.

Price as of · Last analyzed: Jun 14, 2026
Manhattan Scientifics, Inc. operates as an innovation hub focused on advancing nanotechnology and nanomedicine to enhance human life in the U.S. As an OTC Other listed company, it functions as a technology incubator, commercializing early-stage technologies in high-growth sectors with inherent risks.

Analyst Coverage for MHTX: MHTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • AEMD · Aethlon Medical, Inc. · 31 /100
  • HYPD · Hyperion DeFi, Inc. · 39 /100
  • LNSR · LENSAR, Inc. · 44 /100

See all scored stocks →

Manhattan Scientifics, Inc. (MHTX) Healthcare & Pipeline Overview

CEOEmmanuel Tsoupanarias
Employees1
HeadquartersNew York City, US
IPO Year1998

Manhattan Scientifics, Inc. (MHTX) functions as an innovation hub, specializing in the advancement and market introduction of nanotechnology and nanomedicine technologies across the United States. Established in 1992, the company focuses on developing disruptive solutions aimed at enhancing human life, positioning itself within the healthcare sector as an early-stage technology incubator.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for MHTX?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Manhattan Scientifics, Inc. (MHTX) presents an investment profile centered on its role as an innovation hub and technology incubator, specializing in the advancement of nanotechnology and nanomedicine. The core value driver lies in its portfolio of early-stage, potentially disruptive technologies, offering investors exposure to high-growth sectors within healthcare. The company's strategy involves identifying and commercializing these nascent innovations, aiming to enhance human life across the United States. However, the investment thesis is significantly shaped by MHTX's operational characteristics and market listing. With a reported market capitalization of $0.00 billion and a high beta of 9.04, the stock exhibits extreme volatility and a highly speculative nature, indicative of its early development stage and limited operational scale, currently with one employee. As an OTC Other listed company, MHTX faces inherent risks including limited regulatory oversight and potential liquidity challenges, which necessitate close monitoring of its ability to secure adequate funding and successfully transition its technologies from development to commercialization. Future growth catalysts would likely stem from successful clinical trials, regulatory approvals, or strategic partnerships for its incubated technologies, while the primary risk remains the inherent uncertainty of early-stage technology commercialization and funding.

Based on FMP financials and quantitative analysis

MHTX Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Operates as an innovation hub focused on nanotechnology and nanomedicine, targeting high-growth sectors within healthcare.

  • Maintains a lean operational structure with 1 employee, indicating a focus on incubation and external partnerships.
  • Exhibits a market capitalization of $0.00 billion, reflecting its early-stage development and limited market valuation.
  • Demonstrates high market volatility with a beta of 9.04, signifying significant price fluctuations relative to the broader market.
  • Trades on the OTC Other market, implying reduced regulatory oversight and potential liquidity challenges for investors.

Who Are MHTX's Competitors?

MHTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
AEMD Aethlon Medical, Inc. $5.11 +0.59% $8.21M 31 5-pillar
HYPD Hyperion DeFi, Inc. $2.38 -0.21% $36.2M 39 5-pillar
LNSR LENSAR, Inc. $4.85 -1.22% $59.6M 44 5-pillar
HSDT Solana Company $1.63 -0.31% $103M 43 5-pillar
APYX Apyx Medical Corporation $2.49 -2.54% $105M 33 5-pillar
OWLT Owlet, Inc. $3.67 +12.92% $110M 41 5-pillar
INGN Inogen, Inc. $5.57 -2.02% $145M 37 5-pillar
ANIK Anika Therapeutics, Inc. $13.62 +5.99% $182M 71 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MHTX's Key Strengths?

Specialized focus on high-growth nanotechnology and nanomedicine sectors.

  • Innovation hub model allows for agile development of disruptive technologies.
  • Portfolio of early-stage technologies offers exposure to future market leaders.
  • Lean operational structure with 1 employee, potentially minimizing overhead.

What Are MHTX's Weaknesses?

Limited operational scale with only one employee.

  • Market capitalization of $0.00 billion indicates very early stage or minimal valuation.
  • High beta (9.04) suggests extreme price volatility and speculative nature.
  • Reliance on external funding for technology commercialization.

What Are the Key Risks for MHTX?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • Significant liquidity challenges and limited regulatory oversight due to OTC Other listing.
  • High operational risk associated with early-stage technology commercialization and market adoption uncertainty.
  • Inability to secure sufficient funding to advance its nanotechnology and nanomedicine projects.
  • Intense competition from larger, better-funded companies in the healthcare and medical device sectors.
  • Failure to achieve necessary regulatory approvals for its medical technologies.

What Threats Does MHTX Face?

  • Significant regulatory hurdles and lengthy approval processes in healthcare.
  • Intense competition from well-funded research institutions and large corporations.
  • Challenges in securing adequate funding for R&D and commercialization.
  • High risk of technology failure or market adoption issues for early-stage innovations.

What Are MHTX's Competitive Advantages?

  • Specialized focus and expertise in nanotechnology and nanomedicine.
  • Portfolio of early-stage, potentially disruptive technologies.
  • Agile innovation hub model for rapid development and commercialization.
  • Potential for strong intellectual property derived from incubated technologies.

What Does MHTX Do?

Manhattan Scientifics, Inc., established in 1992 and formerly known as Grand Enterprises, Inc., operates as a dedicated innovation hub headquartered in New York City, United States. The company's core mission revolves around the advancement and market introduction of pioneering technologies specifically designed to enhance human life. Its strategic focus is intensely concentrated within the burgeoning fields of nanotechnology and nanomedicine, areas recognized for their potential to revolutionize various aspects of healthcare and beyond. As a technology incubator, Manhattan Scientifics, Inc. strategically identifies, develops, and seeks to commercialize potentially disruptive technologies. This operational model positions the company at the forefront of early-stage technological innovation, aiming to bring groundbreaking scientific discoveries from the laboratory to practical application. The firm's efforts are geared towards building a portfolio of such nascent technologies, thereby offering exposure to high-growth sectors that are often characterized by significant research and development requirements and long commercialization cycles. With a lean operational structure, evidenced by its single employee, the company's approach emphasizes external partnerships and collaborative development to leverage specialized expertise and resources. Manhattan Scientifics, Inc. aims to play a pivotal role in translating complex scientific concepts into tangible products or services that can address unmet needs and improve quality of life across the United States. Its historical evolution from Grand Enterprises, Inc. to its current identity reflects a strategic pivot towards specialized high-tech sectors, underscoring a commitment to innovation-driven growth within the healthcare technology landscape. The company's model as an innovation hub suggests a focus on nurturing and scaling technologies rather than direct large-scale manufacturing or service delivery, relying on the successful commercialization of its intellectual property or incubated ventures.

What Products and Services Does MHTX Offer?

  • Operates as an innovation hub and technology incubator.
  • Focuses on advancing and introducing technologies to enhance human life.
  • Specializes in the fields of nanotechnology and nanomedicine.
  • Identifies and develops potentially disruptive early-stage technologies.
  • Aims to commercialize innovations in high-growth sectors.
  • Seeks to bring scientific discoveries from research to practical application.
  • Headquartered in New York City, serving the United States market.

How Does MHTX Make Money?

  • Incubating and developing early-stage technologies in nanotechnology and nanomedicine.
  • Commercializing these technologies through licensing, partnerships, or spin-offs.
  • Generating revenue from successful market introduction of innovative products or services.
  • Potentially through intellectual property sales or royalty agreements.

What Industry Does MHTX Operate In?

Manhattan Scientifics, Inc. operates within the dynamic and rapidly evolving healthcare sector, specifically targeting the Medical - Devices industry through its focus on nanotechnology and nanomedicine. The broader market for nanomedicine is characterized by significant growth potential, driven by advancements in drug delivery systems, diagnostics, and therapeutic applications. This field is projected to expand as research yields more practical applications for nanoscale materials in biological systems. MHTX positions itself not as a direct manufacturer or service provider, but as an innovation hub and technology incubator. This model places it within a competitive landscape populated by both specialized nanotechnology firms and larger pharmaceutical or medical device companies with dedicated R&D arms exploring similar frontiers. The company's strategy is to identify and nurture early-stage technologies, aiming to capture value from their eventual commercialization. Its success is intrinsically linked to the broader trends in scientific discovery and the ability to navigate complex regulatory pathways inherent in the healthcare and medical device industries.

Who Are MHTX's Key Customers?

  • Pharmaceutical companies seeking advanced drug delivery systems.
  • Medical device manufacturers looking for innovative components or products.
  • Healthcare providers adopting new diagnostic tools or therapies.
  • Potentially, end-users or patients benefiting from enhanced medical solutions.
Model self-rating on this text: 66% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage
ROE 67%

Key Financial Metrics

Return on equity for Manhattan Scientifics, Inc. stands at 66.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

Manhattan Scientifics, Inc. operates in the Medical Devices industry within the Healthcare sector. It is headquartered in New York, United States.

F-Score 2/9

Financial Health

Manhattan Scientifics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Net buying

Insider Activity

12 transactions · 3 purchases, 0 sales, 9 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

MHTX Latest News

No recent news available for MHTX.

MHTX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MHTX.

Price Targets

Wall Street price target analysis for MHTX.

MHTX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MHTX; grades run from A+ (80-100) to F (below 30).

MHTX OTC Market Information

Manhattan Scientifics, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not required to meet minimum financial standards or adhere to strict reporting requirements. This tier typically includes companies with limited public information, distressed financials, or those that are not current in their disclosures. This contrasts sharply with NYSE and NASDAQ, which demand rigorous financial reporting, corporate governance, and minimum share price/market capitalization for listing, providing investors with greater transparency and liquidity.

  • OTC Tier: OTC Other
Liquidity: As an OTC Other listed company, Manhattan Scientifics, Inc. likely experiences significant liquidity challenges. The absence of a major exchange listing often results in lower trading volumes, wider bid-ask spreads, and increased difficulty for investors to buy or sell shares at desired prices. This limited liquidity can lead to greater price volatility and make it challenging to execute trades efficiently, particularly for larger positions. Investors should anticipate potential difficulties in entering or exiting positions due to the thin trading environment typical of this market tier.
OTC Risk Factors:
  • Limited regulatory oversight and disclosure requirements.
  • Potential for low trading volume and illiquidity, making shares difficult to trade.
  • Increased susceptibility to market manipulation due to less transparency.
  • Difficulty in obtaining reliable financial information and company updates.
  • Higher volatility and potential for significant price fluctuations.
Due Diligence Checklist:
  • Verify the company's current financial statements and disclosure status, if available.
  • Research any recent news, press releases, or corporate actions from official sources.
  • Assess the commercial viability and market potential of its core technologies.
  • Investigate the backgrounds and track records of management and key personnel.
  • Understand the company's funding strategy and capital requirements for commercialization.
  • Evaluate the intellectual property portfolio and its protection.
  • Consult with a financial advisor experienced in OTC markets.
Legitimacy Signals:
  • Clear and consistent communication of business strategy and progress.
  • Demonstrable progress in technology development or commercialization.
  • Formation of credible strategic partnerships or licensing agreements.
  • Adherence to any voluntary disclosure standards, even if not mandated.
  • Presence of a functional website with updated company information.

Manhattan Scientifics, Inc. Healthcare Stock: Key Questions Answered

How does Manhattan Scientifics, Inc. navigate the regulatory landscape for its nanomedicine technologies?

Manhattan Scientifics, Inc. operates within the highly regulated healthcare sector, where its nanomedicine technologies would be subject to stringent regulatory approval processes, primarily by the FDA in the United States.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited specific project details available for growth opportunities and CEO track record.
  • FAQ answers are constructed based on the company's stated focus areas and industry context due to limited specific operational details.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives